AbCellera Investor Conference Presentation Deck

CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 9 WE ASKED OURSELVES... IS IT VALUABLE? + Accelerating approval of an average antibody drug by 1 year could be worth more than $200M in NPV + Being first to market could easily be billions in sales, profit, and value + Drugging the undruggable could unlock >$100 billion in new market opportunities + Saving small biotechs from reinventing the wheel could be worth more than $50 million

View entire presentation